Stockholders' Equity - Additional Information (Detail) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12 Months Ended |
|
|
|
|
|
Jan. 02, 2016 |
Dec. 31, 2015 |
Aug. 12, 2015 |
Jul. 13, 2015 |
Jun. 23, 2015 |
Mar. 09, 2015 |
Jan. 02, 2015 |
Nov. 07, 2014 |
Aug. 27, 2014 |
Jul. 22, 2014 |
Jul. 13, 2014 |
Feb. 10, 2014 |
Dec. 19, 2013 |
Sep. 23, 2013 |
Jul. 12, 2013 |
Jun. 06, 2013 |
Apr. 26, 2013 |
Nov. 08, 2012 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Nov. 30, 2014 |
Jul. 26, 2013 |
Apr. 18, 2013 |
Mar. 23, 2013 |
Dec. 31, 2012 |
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, shares authorized |
|
1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000,000
|
1,000,000
|
1,000,000
|
|
|
|
|
|
Preferred stock, shares outstanding |
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
|
|
|
|
Common stock, shares issued |
|
58,228,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
58,228,000
|
58,115,000
|
|
|
|
|
|
|
Common stock, shares outstanding |
|
58,228,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
58,228,000
|
58,115,000
|
37,422,753
|
|
|
|
|
|
Common stock, shares authorized |
|
100,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000,000
|
100,000,000
|
|
|
|
|
|
|
Proceeds from equity offering, net of expenses |
|
|
|
|
|
|
|
$ 34,800,000
|
|
$ 11,500,000
|
|
$ 4,800,000
|
|
|
|
|
|
|
|
$ 51,118,000
|
$ 5,201,000
|
|
|
|
|
|
Maximum stock offering price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,000,000
|
|
|
|
Dividend Declared |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
|
|
Warrants and rights outstanding |
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
Minimum required closing price of common stock on the NASDAQ in order to exercise |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6.00
|
|
Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,350,000
|
$ 1,233,000
|
$ 1,609,000
|
|
|
|
|
|
Common stock issued pursuant to options exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38,000
|
153,000
|
343,000
|
|
|
|
|
|
Options outstanding |
|
4,493,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,493,000
|
3,475,000
|
4,441,000
|
|
|
|
|
3,860,000
|
Expected term (years) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years 9 months 18 days
|
3 years 9 months 29 days
|
3 years 7 months 24 days
|
|
|
|
|
|
Volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90.00%
|
94.00%
|
84.00%
|
|
|
|
|
|
Risk-free interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.64%
|
1.66%
|
1.04%
|
|
|
|
|
|
Coo |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted to COO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
350,000
|
|
|
|
|
|
|
|
|
|
|
Stock options granted at an exercise price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4.00
|
|
|
|
|
|
|
|
|
|
|
Stock options vesting beginning date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jun. 06, 2014
|
|
|
|
|
|
|
|
|
|
|
Unvested stock options forfeited |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
306,250
|
|
|
|
|
|
|
Stock options expiration date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Feb. 28, 2016
|
|
|
|
|
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares vested and exercised consecutive term |
|
|
|
36 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Financial Officer | Vest on January 2, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted |
|
|
|
|
|
523,026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share based compensation arrangement by share Based payment award fair value price |
|
|
|
|
|
$ 1.48
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected term (years) |
|
|
|
|
|
6 years 1 month 6 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volatility |
|
|
|
|
|
88.79%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Risk-free interest rate |
|
|
|
|
|
1.83%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Financial Officer | CFO Grant Award Tranche Two |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted |
|
|
|
|
|
348,684
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares vested and exercisable date |
|
|
|
|
|
Mar. 09, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share based compensation arrangement by share Based payment award fair value price |
|
|
|
|
|
$ 1.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected term (years) |
|
|
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volatility |
|
|
|
|
|
87.87%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Risk-free interest rate |
|
|
|
|
|
2.19%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option shares vested and exercised |
|
100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2002 Stock Incentive Plan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan expiration date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
May 05, 2019
|
|
|
|
|
|
|
|
Common stock authorized for issuance under the 2002 Plan |
|
11,550,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,550,000
|
|
|
|
|
|
|
|
Common stock issued pursuant to options exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,068,000
|
|
|
|
|
|
|
|
Options outstanding |
|
4,493,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,493,000
|
|
|
|
|
|
|
|
Options available for future grant |
|
3,989,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,989,000
|
|
|
|
|
|
|
|
Non-qualified Stock Options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options available for future grant |
|
|
|
|
|
|
|
|
|
|
172,282
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted at an exercise price |
|
|
|
|
|
|
|
|
|
|
$ 1.98
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise Price of Stock Options |
|
|
|
|
|
|
$ 2.64
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-qualified Stock Options | Officers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted |
|
|
|
|
|
|
1,365,702
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options expiration period |
|
|
|
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options vesting description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i) as to 50% of the options, one-fourth on the one year anniversary of the grant date and the remaining three-fourths, ratably over the next 36 month period, commencing on the thirteenth month from grant date over a requisite service period of four years, and (ii) as to 50% of the options, upon achievement of specific annual Company performance criteria with a requisite service period of one year.
|
|
|
|
|
|
|
|
Non-qualified Stock Options | Consultants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted |
|
|
|
|
|
|
86,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options expiration period |
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-qualified Stock Options | Officers And Consultant | Two Thousand Fifteen Compensation Plan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Decrease in fair value awards |
|
|
$ 661,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional compensation expense related to modification |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 154,000
|
|
|
|
|
|
|
|
Shares issued for settlement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
122,038
|
|
|
|
|
|
|
|
Non-qualified Stock Options | Officers And Consultant | Two Thousand Fifteen Compensation Plan | Subsequent Event |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrant vesting upon early termination |
488,170
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-qualified Stock Options | Officers And Consultant | Two Thousand Fifteen Compensation Plan | Vest on January 2, 2016 | Subsequent Event |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage on performance optional vesting |
80.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-qualified Stock Options | Chief Executive Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted at an exercise price |
|
|
|
$ 1.64
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted |
|
|
|
870,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise Price of Stock Options |
|
|
|
$ 1.64
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options expiration period |
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period |
|
|
|
4 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-qualified Stock Options | Chief Financial Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted at an exercise price |
|
|
|
|
|
$ 1.99
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted |
|
|
|
|
|
871,710
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options expiration period |
|
|
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted Stock Units (RSUs) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options available for future grant |
|
|
|
|
|
|
|
|
|
|
37,879
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise Price of Stock Options |
|
|
|
|
|
|
|
|
|
|
$ 1.98
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted Stock Units (RSUs) | One Independent Directors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period |
|
|
|
|
|
|
|
|
9,217
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted Stock Units (RSUs) | Four Independent Director |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period |
|
|
|
|
|
|
|
|
37,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation arrangement by share-based payment award, equity instruments other than options, value per share |
|
|
|
|
|
|
|
|
$ 2.17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period |
|
|
|
|
|
|
|
|
12 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
One Year Anniversary | Chief Executive Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option shares vested and exercised |
|
|
|
217,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
One Year Anniversary | Chief Financial Officer | Vest on January 2, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option shares vested and exercised |
|
|
|
|
|
130,757
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares vested and exercised consecutive term |
|
|
|
|
|
35 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares vested and exercisable date |
|
|
|
|
|
Mar. 09, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thirty Six Month Anniversary | Chief Financial Officer | Vest on January 2, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option shares vested and exercised |
|
|
|
|
|
10,909
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares vested and exercisable date |
|
|
|
|
|
Mar. 09, 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Vesting And Becoming Exercisable Each Month | Chief Executive Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option shares vested and exercised |
|
|
|
18,125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Vesting And Becoming Exercisable Each Month | Chief Financial Officer | Vest on January 2, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option shares vested and exercised |
|
|
|
|
|
10,896
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ten Year Anniversary | Chief Financial Officer | CFO Grant Award Tranche Two |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option shares vested and exercised |
|
|
|
|
100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares vested and exercisable date |
|
|
|
|
Mar. 09, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option shares vested and exercised |
|
|
|
|
248,684
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sun Dental Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5.90
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
$ 0
|
|
|
|
|
|
|
Plan expiration date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Apr. 24, 2014
|
|
|
|
|
|
|
Sun Dental Warrant vesting rate per assisted sale |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000
|
|
|
|
|
|
|
|
|
|
2013 IR Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5.10
|
|
|
Stock-based compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
$ 0
|
$ 0
|
|
|
|
|
|
Minimum required closing price of common stock on the NASDAQ in order to exercise |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 7.50
|
|
|
CMR Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
$ 0
|
0
|
|
|
|
|
|
2012 IR Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2.50
|
|
|
|
|
|
|
|
|
Minimum required closing price of common stock on the NASDAQ in order to exercise |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 7.00
|
|
|
|
|
|
|
|
|
Number of warrant vesting upon early termination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
|
|
|
|
|
|
|
|
Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 64,000
|
|
|
|
|
|
Stock based compensation, shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,296
|
|
|
|
|
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued to purchase common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,205,862
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4.00
|
|
|
|
|
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
9,205,862
|
1,025,000
|
|
|
|
|
|
Northland Securities Inc |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of stock, net, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
2,688,172
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued, price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.86
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from equity offering, gross |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments of stock issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
408,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from equity offering, net of expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4,600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Valam First Tranche |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued to purchase common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
165,000
|
|
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4.00
|
|
|
|
|
|
|
|
|
|
|
|
Vesting of Valam warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30,000
|
|
|
|
|
|
|
|
|
|
|
|
Warrants and rights outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30,000
|
30,000
|
|
|
|
|
|
Stock-based compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 41,000
|
$ 41,000
|
|
|
|
|
|
Valam | Original Agreed Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6.00
|
|
|
|
|
|
|
|
|
|
|
|
Plan expiration date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jul. 14, 2020
|
|
|
|
|
|
|
FDA Clearance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vesting of Valam warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
55,000
|
|
|
|
|
|
|
|
|
|
|
|
Second Ent Laser |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vesting of Valam warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000
|
|
|
|
|
|
|
|
|
|
|
|
ENT laser revenues required during a 12-month period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000,000
|
|
|
|
|
|
Third Ent Laser |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vesting of Valam warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000
|
|
|
|
|
|
|
|
|
|
|
|
ENT laser revenues required during a 12-month period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000,000
|
|
|
|
|
|
Oracle Group |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of stock, net, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
340,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued, price per share |
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.80
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from equity offering, gross |
|
|
|
|
|
|
|
|
|
|
|
|
$ 612,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments of stock issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
30,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from equity offering, net of expenses |
|
|
|
|
|
|
|
|
|
|
|
|
$ 582,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2014 Common Stock Issuances |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of stock, net, shares |
|
|
|
|
|
|
|
14,162,873
|
|
6,250,000
|
|
1,945,525
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued, price per share |
|
|
|
|
|
|
|
$ 2.39
|
|
$ 1.92
|
|
$ 2.57
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued to purchase common stock |
|
|
|
|
|
|
|
9,205,862
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
|
|
$ 4.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from equity offering, gross |
|
|
|
|
|
|
|
$ 35,000,000
|
|
$ 12,000,000
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments of stock issuance costs |
|
|
|
|
|
|
|
235,000
|
|
462,000
|
|
188,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from equity offering, net of expenses |
|
|
|
|
|
|
|
$ 34,800,000
|
|
$ 11,500,000
|
|
$ 4,800,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercisable |
|
|
|
|
|
|
|
May 07, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued for term |
|
|
|
|
|
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, shares authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000,000
|
|
|
|
|
|
|
Maximum | Sun Dental Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued to purchase common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,000
|
|
|
|
|
|
Maximum | 2013 IR Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued to purchase common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60,000
|
|
|
Maximum | CMR Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued to purchase common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
Maximum | CMR Warrant | First Tranche |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued to purchase common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4.50
|
|
Maximum | CMR Warrant | Mar. 23, 2013 Maximum Second Tranche CMR Warrant Cancelled Dec 2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4.50
|
|
Maximum | CMR Warrant Cancelled Dec 2013 | First Tranche |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued to purchase common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
|
|
|
|
Maximum | CMR Warrant Cancelled Dec 2013 | Mar. 23, 2013 Maximum Second Tranche CMR Warrant Cancelled Dec 2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued to purchase common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
|
|
|
Maximum | 2012 IR Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued to purchase common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
Series B Junior Participating Cumulative Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, shares authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500,000
|
|
|
|
|
|
|